It has been suggested that genes that regulate apoptotic cell death may play an important role in determining the sensitivity of tumor cells to chemotherapy. W e have recently cloned a member of the bcl-2 family, bcl-x. To test whether bcl-xL exprassion affects the sensitivity of tumor cells to chemotherapy, we have created stable cell lines overexpressing bcl-xL and have tested these cells for resistance to cell death induced by metabolic inhibitors and chemotherapeutic agents. Bcl-xL expression dramatically reduces the cytotoxicity of bleomycin, cisplatin, etoposide, vincristine, hygromycin B, and mycophenolic acid for up to 4 days in culture. BcI-xL does not prevent cells from undergoing cell cycle arrest in response to these drugs, but rather prevents treated cells from undergoing apoptosis. Cell-cycle analysis on cells treated with the chemotherapeutic agents bleomycin, cis-
amino acids shared among the bcl-2 family members. Bclxs antagonizes the death inhibiting activity of both bcl-2 and bc1-xLZ2 (A.J.M., unpublished data, July 1994).
The purpose of this study was to determine if bcl-xL could protect cells from cell death induced by factors other than growth factor withdrawal. In particular, because recent observations in our laboratory have shown that bcl-x, can be highly expressed in some hematopoietic and solid tumors (L.H.B., unpublished data, June 1994; Dole et al, submitted), we wished to study the effectiveness of bcl-x, in conferring resistance to cell death in response to a wide variety of chemotherapeutic agents. Finally, although apoptosis has been found to occur in all phases of the cell cycle, little work has been done to address whether genes such as bclx, can block cell death outside G1. Because various antineoplastic drugs target processes that are restricted to specific places in the cell cycle, we wished to see if bcl-xL can protect cells from apoptotic stimuli acting at distinct positions within the cell cycle. Bcl-xL expression levels in transfected cell lines. FL5.12 cells were transfected with either an empty pSFFV-Neo expression vector (FE-Neol, or pSFFV-Neo with a bcl-x' cDNA insert. The latter was cloned by limiting dilution and a representative clone was used in this study (FL5-bcl-xJ. To compare the expression levels of bcl-xL between FL5-Neo and FL5-bcl-xb 5 x 10' cells from each were lysed in NET-N. and the proteins separated on a 15% SDS polyacrylamide gel. The gel was blotted and then probed with 13.4, a rabbit polyclonal antibody against bcl-x. BCI-XL migrates at an apparent molecular weight of approximately 29 kD. mL of (3418. Bulk transfectants were cloned by limiting dilution, and clones that expressed high levels of bcl-xL were screened by immunoblot and used in the functional studies.
For the drug studies, cells were initially cultured at 5 X lo' cells/ mL in the presence of drug at a concentration previously determined by dose titration to be effective at killing FL5.12 cells. The drug concentrations used are as follows: 3 mg/mL hygromycin B, 30 pgl mL mycophenolic acid, 5 pg/mL cisplatin, 50 mU/mL bleomycin, I O pg/mL etoposide, 0.1 pg/mL vincristine, and I pmol/L doxorubicin. For irradiation studies, cells were irradiated with 20 Gy from a cesium source. Viability was determined at each time point by resuspending approximately 5 X IO' cells in 500 pL of fluorescenceactivated cell sorting (FACS) buffer (0.1 % sodium azide, 1 % bovine serum albumin, in Ix phosphate-buffered saline [PBS], pH 7.4) with 2 pL of 0.5 mg/mL of propidium iodide, and analyzing the cells for uptake of propidium iodide on a fluorescence-activated cell sorter (Becton Dickinson, San Jose, CA).
Imrnunoblorring Cells were harvested and lysed in NET-N buffer (100 m m o n NaCI, 1 mmol/L EDTA, 20 mmol/L TRIS, 1% NP-40, 80 pg/mL aprotinin, 20 pg/mL leupeptin, 170 pg/mL phenylmethylsulfonyl), and the protein was quantitated with the BCA Protein Assay kit (Pierce). Seventy-five micrograms of protein was loaded in each lane of a 15% sodium dodecyl sulfate (SDS)-polyacrylamide gel. The gel was blotted to nitrocellulose and blocked with blotto (5% nonfat dry milk + 0.2% Tween-20) for I hour at room temperature. The blot was then probed with 1:lOOO dilution of 13.4, a rabbit anti-bcl-x polyclonal antibody in blotto for I hour at room temperature, washed twice with TBS + 0.2% Tween-20 for IO minutes each, and probed again with a I : 2OOO dilution of horse radish peroxidase (HRP)-conjugated antirabbit secondary antibody in blotto. The blot was then washed as before and developed with the enhanced chemiluminescence (ECL) system (Amersham, Arlington Heights, IL).
Cell cycle analysis. Approximately 1 X IO6 cells were pulsed for 30 minutes with 25 pmol/L of bromodeoxyuridine (Boehringer Mannheim, Mannheim, Germany), harvested, resuspended in 500 pL of PBS, and fixed with 2 mL of 100% ethanol. .600 mmol/L NaCI, 10 mmol/L EDTA) and 250 pg/mL of proteinase K was added. The sample was incubated at 50°C for 1 to 2 hours, after which time another 125 pg/mL of proteinase K was added, and the sample was further incubated at 50°C for 1 hour to overnight. Two hundred fifty microliters of 7.5 mol/L ammonium acetate was added and the sample rocked for 15 minutes at room temperature. Seven hundred fifty microliters of isopropanol was added and the sample rocked for 30 minutes. The sample was centrifuged for IO minutes at 16,000g in a bench-top centrifuge and the pellet was washed twice with 70% ethanol + 50 mmol/L NaCI. The pellet was dried and resuspended in 500 p L of TE (10 mmol/L TRIS, I mmo/L EDTA, pH 8.0).
Two microliters of 10 mg/mL RNase A was added and the sample incubated at 37°C for 1 hour. The sample was precipitated with I / 10 v01 3 moVL sodium acetate and 2.5 v01 of 100% ethanol, spun at 16,000g in a bench-top microfuge, and washed with 70% ethanol.
The DNA pellet was dried and resuspended in 100 p L of TE. Two micrograms of DNA was loaded on a 2.0% agarose gel.
RESULTS

Bcl-x, protects cells from apoptosis induced by metabolic inhibitors.
The murine interleukin-3-dependent prolymphocytic cell line FL5.12 was transfected with the human bcl-x, cDNA inserted into the pSFFV-Neo expression vector and cloned by limiting dilution. To determine if overexpression of bcl-xL could protect FL5.12 cells from various metabolic inhibitors and chemotherapeutic agents, bulk transfectants and/or several isolated clones were tested. A single clone that expresses a high level of bcl-xL (Fig I ) was used in the studies presented here to allow comparison of results from different drugs. However, the results from the bulk transfectants and other clones were similar (data not shown).
Hygromycin B, a protein synthesis inhibitor commonly used in the selection of drug-resistant transfectants, killed FL5.12 cells transfected with the neomycin-resistance plasmid alone (FLs-Neo) as determined by propidium iodide exclusion. In contrast, FL5.12 cells that overexpressed bclxL (FLS-bcl-xL) were resistant to cell death in response to hygromycin B treatment (Fig 2) . Even after 5 days of culture with hygromycin B, FL5-bcl-xL cells were still nearly 50% viable. Mycophenolic acid, an inhibitor of guanine biosynthesis and another drug commonly used for the selection of stable transfectants, also rapidly killed FL5-Ne0 cells (Fig  2) . Once again, bcl-xL dramatically antagonized the lethal effects of this drug. Both hygromycin B and mycophenolic acid induced cell death with the characteristic features of apoptosis (see below).
Cell counts of the drug-treated cells showed that the cells were no longer proliferating. To determine which cell-cycle populations bcl-x, could protect, cell-cycle analysis was performed by BrdU incorporation and DNA staining. Cells treated with hygromycin B were arrested predominantly in GI, a cell-cycle population that we and others have shown can be protected by overexpression of bcl-xL or bcl-2 (data not shown). However, we found that cells treated with mycophenolic acid arrested in all phases of the cell cycle (Fig 3) . Untreated cells were actively cycling, with nearly half of the cells incorporating BrdU and having between a 2N and a 4N DNA content. In contrast, cells treated with mycophenolic acid stopped incorporating BrdU by 24 hours and arrested in G1, S, and GUM. The S-phase-arrested population seemed to be more susceptible to cell death because the percentage of cells in this population in FLS-Neo cells decreases between 24 and 48 hours, from 32.2% to 17.8%. However, the arrested S-phase population appears to be at least partially protected by bcl-x, because, in FLS-bcl-x, cells, 42.7% of the cell population is maintained in this state at 72 hours. By 120 hours, this population decreases to 14.8%, suggesting that cells arrested in S phase after mycophenolic acid treatment preferentially undergo apoptosis. Although we cannot rule out that the arrested Sphase cells are slowly progressing into another phase of the cell cycle, the nearly complete absence of a BrdU-positive population argues against this possibility. Furthermore, if slow progression out of S phase was occurring, one might expect to see a kinetically equivalent decrease in the percentage of arrested S-phase cells in both FLS-Neo and FLS-bclxL cells. However, this is not the case because the former show a much quicker decrease in the percentage of S-phasearrested cells. These data suggest that bcl-x, is able to protect cells in multiple places in the cell cycle.
Bcl-x, protects cells from apoptosis induced by antineoplastic agents. To further characterize the ability of bcl-x, to protect from multiple apoptotic stimuli and its ability to protect in different phases of the cell cycle, we chose to examine the effects of treating FLS-bcl-x, cells with various antineoplastic agents known to target different processes involved in cell-cycle progression. Bleomycin and cisplatin are thought to function as DNA damaging agents. Etoposide is an inhibitor of topoisomerase 11. Vincristine is an inhibitor of tubulin polymerizati~n.~~ FL5-Neo and FL5-bcl-x, were treated with each of these chemotherapeutic drugs and viability was assessed over 4 days. Bleomycin, cisplatin, etoposide, and vincristine all caused extensive apoptosis in FLS-Neo cells, with all but the bleomycin-treated cells being nearly completely dead by 48 hours (Figs 4 and S ) . In contrast, FLS-bcl-x, cells were resistant to cell death when kept in continuous culture with drug. In all cases, the treated FL5-b~l-x~ cells were well over 50% viable even after 96 hours of treatment. FLS-bclxL cells were also highly resistant to apoptosis induced by gamma irradiation and doxorubicin (data not shown).
Bcl-x, expression also had a dramatic effect on dose response to the various drugs. Shown in Fig 6 are the doseresponse curves for cisplatin and etoposide. FLS-bcl-xL cells were more resistant to the cytotoxic effects of cisplatin by at least two orders of magnitude relative to FLS-Ne0 cells. Etoposide-treated FLS-bcl-x, cells were more than three orders of magnitude more resistant than FLS-Neo cells. We medium alone (lanes 1 and 2). hygromycin B (lanes 3 and 41, mycophenolic acid (lanes 5 and 6) . 81, cisplatin (lanes 9 and 101, etoposide (lanes  11 and 12). and vincristine (lanes 13 and 141. have also treated FLS-bcl-x, cells with vincristine at concentrations over four orders of magnitude greater than the concentration that effectively killed FLS-Neo cells. but could not get comparable killing (data not shown).
bleomycin (lanes 7 and
Bcl-xl. can protect in multiple places i n the cell cycle. Other types of drug resistance, such as resistance mediated by mdrl, work by decreasing the effective cellular concentration of drugs, making the cells insensitive not only to the drugs' cytotoxic effects, but also to other effects. To distinguish the multidrug resistance phenotype conferred by bclxI. from that conferred by rndrl, we performed cell-cycle analysis on FL5-bcl-x, cells after drug treatment to show that, despite the decrease in cytotoxicity, the drugs were still affecting the cells by causing cell-cycle-specific growth arrest. Untreated FLS-bcl-x,. cells were actively in cell cycle, with 41.6% of the cells incorporating BrdU and having between a 2N and 4N DNA content (Fig 7) . Although proceeding with different kinetics, all of the drugs that we analyzed caused a markedly reduced uptake of BrdU, indicating growth arrest. Figure 7 shows the cell-cycle profile of FLSbcl-xL cells treated with drugs that induce arrest at different points in the cell cycle. Bleomycin caused growth arrest with the slowest kinetics of all of the drugs tested, but by 96 hours, the majority of cells were arrested in G 1. A substantial S-phase arrest occurred after etoposide treatment. By 24 hours, 43.6% of the cells were arrested in S phase, and at 96 hours, over half of the cells were arrested in S phase. This growth arrest was confirmed by 'H-thymidine incorporation. FLS-bcl-xl. cells treated with etoposide had a greater than 300-fold decrease in 'H-thymidine incorporation after 48 hours of drug treatment (data not shown). Cisplatin caused an accumulation of cells in what appears to be the late Sphase-G2 boundary. The G2/M block caused by vincristine was apparent by 24 hours, and by 96 hours, 87.8% of the cells were blocked in this stage of the cell cycle. Cell-cycle analysis of FLS-Neo cells at 24 hours after drug treatment is comparable with FLS-bcl-xl-cells (data not shown). At later time points the profile of FLS-Neo cells contain too 1907 many cells undergoing apoptotic cell death to allow for quantitative cell-cycle analysis. From these data it is apparent that each of the chemotherapeutic agents is significantly inhibiting the ability of bcl-x,-transfected cells from proliferating even though the cells are prevented from undergoing apoptosis. Together with the viability data, these results argue that bcl-xl. can protect cells in all stages of the cell cycle.
Cells protected l>? hcl-x, retain the crbilih to proliferate ofter removd of drugs. An important property of chemotherapeutic resistant tumors is that they retain the ability to proliferate after drug clearance. We wished to see if bcl-xl~ could confer such a property. To this end, after 96 hours of drug treatment, FLS-bcl-xl-cells were washed three times 2N and a 4N DNA content. The majority of the cells that are incorporating BrdU have between a 4N and an 8N DNA content. This suggests that the vincristine-treated cells that fail to undergo apoptosis can reenter the cell cycle without completing mitosis, resulting in a polyploid cell population.
DISCUSSION
We show in this study that bcl-x,, can confer a multidrug resistance phenotype. The drugs tested interfere with cell physiology by multiple distinct mechanisms and act in various points in the cell cycle. Yet, regardless of the mechanism or the cell cycle stage affected, bcl-xL could protect from programmed cell death. Furthermore, cells arrested by the drugs retain the ability to proliferate after the drug was removed from culture.
Programmed cell death is thought to be a genetically encoded process that cells actively engage in response to various stressful stimuli. In our study we examined the effects of metabolic inhibitors, DNA damaging agents, microtubule inhibitors, and topoisomerase inhibitors. Traditional interpretation of the mechanism by which metabolic inhibitors or DNA damaging agents cause cell death would be that the cell passively dies as a result of exhausting a critical protein or becoming inflicted with irreparable damage. However, the antiapoptotic effects of genes like hcl-x,, would suggest that cells are not passively killed as a result of such insults; rather, the cells actively initiate a cell death program in response to the damage. Cells may choose to die because apoptosis is the default fate of cells undergoing prolonged cell-cycle arrest.
If apoptosis is one potential outcome of various cell-cycle checkpoint controls, it makes sense that cells can undergo apoptosis in multiple stages in the cell cycle. Studies have shown that c-myc-induced apoptosis can occur at GI and S, 7 and p53 can cause G1 arrest and apoptosis as a result of DNA damage.'4-27 However, there has been little direct 
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evidence that cells can be protected from cell death from multiple places in the cell cycle. Our study clearly shows that bcl-x, can protect in GI, S , and G2/M. Furthermore, in the case of cell death induced by mycophenolic acid, bcl-x, seems to protect better in G1 and G2/M than in S phase. Other studies have shown situations in which S-phase cells are more susceptible to apoptosis. Meikrantz et al" recently showed that multiple forms of apoptosis can be potentiated by using S-phase-arrested cells compared with an asynchronous population. Although our data suggest that S-phasearrested cells are generally more susceptible to apoptosis, bcl-x,, effectively protected cells arrested in S phase by etoposide and cisplatin. Nevertheless, the dose-response data indicate that bcl-x12 is able to protect from vincristine-induced cell death over a much greater range of drug concentrations compared with etoposide and cisplatin.
The demonstration that bcl-x, can confer a multidrug resistant phenotype and allow a cell to remain arrested until it can reacquire the ability to proliferate, make bcl-x, expression a potentially formidable tumor promoter. It has been previously reported that vincristine can induce chromosomal aberrations such as polyploidy." We show that in cells that normally undergo apoptosis after vincristine treatment, bcl- 
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vated protein (MAP) kinase activity." FLS-bcl-x, cells treated with vincristine show elevated cyclin B expression as cells arrest in M phase; however, cyclin B levels cannot be maintained and decrease to undetectable levels while the cells remain arrested (A.J.M., unpublished data, December 1994). Because the degradation of cyclin B is thought to be an important signal for the completion of M phase, its absence when FLS-bcl-x, cells are released from the M phase block may contribute to polyploidy by signaling the cells to reinitiate cell cycle from G1 without completing M phase.
Apoptosis can apparently be triggered by various cellcycle checkpoint controls. Cells suffering any of a variety of insults that could lead to chromosomal aberrations appear to die by apoptosis, a condition which may be advantageous because it prevents cells from accumulating further damage that may lead to oncogenic progression. Additionally, the inability to die in response to cellular damage induced by chemotherapeutic drugs may actually promote tumor progression by increasing mutation frequency. Studies show that p53 may be at the center of many of these types of checkpoint controls, and absence of p53 function can promote tumor formation. Antiapoptotic genes like hcl-x,. can work independently of p53. Bcl-2 can protect thymocytes from p53 knockout mice from apoptosis induced by DNA-damaging drugs and irradiation," and bcl-x, can also protect the p53 mutant Jurkat cell line from apoptosis." Overexpression of bcl-xl. seems to be another way to thwart checkpoint controls. Other than the polyploidy seen with vincristine, we do not know if inhibition of drug-induced cell death by bcl-xld permitted accumulation of mutations or cellular damage that could promote oncogenic progression. The cell-cycle analysis shows that chemotherapeutic agents do cause cell-cycle arrest presumably in response to the damaging effects of the drugs. Therefore, it seems likely that preventing apoptosis after such damage would increase mutation frequency induced by drugs such as bleomycin, cisplatin, and etoposide.
In conclusion, we have shown that bcl-x,. can function in multiple positions within the cell cycle and guard against the cytotoxicity of drugs that disrupt various cellular processes, suggesting that bcl-xL can protect multimodally. The failure to undergo apoptosis in response to drug treatment may contribute to the accumulation of chromosomal aberrations.
